Clin2Atlas
AtlasOther conditionsBlindness and vision loss

Cataract

4Curable or preventable in mostAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251989 — Ketorolac approved (FDA)1997 — Bromfenac approved (FDA)2005 — Nepafenac approved (FDA)
1989: Drug approval — Ketorolac approved (FDA). 1997: Drug approval — Bromfenac approved (FDA). 2005: Drug approval — Nepafenac approved (FDA)

What's being tested now

2008: 1 trials started2011: 1 trials started2013: 2 trials started2015: 1 trials started2016: 3 trials started2018: 1 trials started2019: 1 trials started2020: 3 trials started2021: 1 trials started2022: 12 trials started2023: 15 trials started2024: 42 trials started2025: 68 trials started2026: 58 trials started20102020202668

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 181 active Cataract trials on Clin2 →

Related

GlaucomaAge-related macular degenerationRefraction disordersNear vision lossOther vision loss

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.